Stoke Therapeutics, Inc. (STOK) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
STOK Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Stoke Therapeutics, Inc. (STOK) trades at a price-to-earnings ratio of -273.3x, with a stock price of $32.79 and trailing twelve-month earnings per share of $-2.69.
The current P/E is 1542% below its 5-year average of 18.9x. Over the past five years, STOK's P/E has ranged from a low of 8.4x to a high of 35.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, STOK trades at a 1324% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, STOK trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our STOK DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
STOK P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.9Lowest | - | +68% | |
| $39B | 127.0 | - | +207%Best | |
| $21B | 25.5 | 6.01Best | +171% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
STOK Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $23.50 | $0.67 | 35.1x | +85% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $11.35 | $0.85 | 13.4x | -30% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $6.65 | $0.79 | 8.4x | -56% |
Average P/E for displayed period: 18.9x
See STOK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs STOK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare STOK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSTOK — Frequently Asked Questions
Quick answers to the most common questions about buying STOK stock.
Is STOK stock overvalued or undervalued?
STOK trades at -273.3x P/E, below its 5-year average of 18.9x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does STOK's valuation compare to peers?
Stoke Therapeutics, Inc. P/E of -273.3x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is STOK's PEG ratio?
STOK PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.